In India, cervical cancer contributes to approximately 6 in "29% of all cancers in women. According to data, in India, Mizoram records the highest number of cervical cancer, which is 23.07 per 100,000. On the contrary, the Dibrugarh district in Assam registers the lowest case count which is 4.91per 100,000.
"The cases of cervical cancer in Northeast can be said to be due to the lack of awareness among the female folks. In many parts of our country it is still a matter of shame to talk openly about feminine issues. So in many cases, women prefer to keep it to themselves and when it becomes serious it becomes difficult to save the patient", gynaecologist Dr. Dilip Sharma said. Dr. Sharma also added that the human papillomavirus transmits through sexual contact.
As per sources, an application has also been sent to the National Technical Advisory Group on Immunization and it may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29.India's pioneer drug manufacturer, the Serum Institute of India has come up with a self-produced quadrivalent human papillomavirus (qHPV) vaccine for cervical cancer patients. The Subject Expert Committee of the Drugs Controller General of India on 15 June has recommended this vaccine manufactured by the SII. This vaccine can be given to patients with cervical cancer from the age of 9 to 26 (both girls and boys).
As per sources, an application has also been sent to the National Technical Advisory Group on Immunization and it may take the final decision on the HPV vaccine in the next meeting scheduled to be held on June 29. It was added that the SII are committed to making our country 'ATMANIRBHAR' by the production of India's first indigenous life-saving qHPV Vaccine, which is expected to fulfil Narendra Modi's dream relating to 'vocal for local' and 'Make in India for the world'.